ENDP - BioSpecifics Technologies Could Surge If The FDA Approves Its 'CCH' In XiaFlex To Treat Cellulite In The Buttocks
Our analysis concludes that if the sNDA filed by BioSpecifics Technologies' (BSTC) commercial partner, Endo International PLC (ENDP), for the use of BSTC's injectable collagenase ("CCH") in a product called XiaFlex to treat cellulite of the buttocks, is approved by the FDA as anticipated on July 6, 2020, the resulting XiaFlex sales in this indication could be a BLOCKBUSTER on an unprecedented scale for BSTC's commercial partner ENDP. Our analysis concludes the resulting royalties of between 12 & 12.5% due BSTC from ENDP sales could more than triple current annual BSTC revenues.
Later in this